Astra looks to confirm Datroway's turnaround
The Avanzar study could read out shortly.
The month ahead: July’s upcoming events
Regeneron is facing two FDA decisions for its T-cell engagers.
TuHura makes its bid for Merkel accelerated approval
The company reckons its immunotherapy could improve on Keytruda.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
Deals accompany new phase 1 trial starts
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
